SCHEMBL24251948

SCHEMBL24251948

C=CC(=O)N1CCC(c2cc(C)c3c(N)ncnn23)C1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BTK Q06187 9/20 0.46
EGFR P00533 3/20 0.45
FGFR4 P22455 3/20 0.43
FGFR1 P11362 2/20 0.43
JAK3 P52333 6/20 0.42
JAK2 O60674 5/20 0.42
JAK1 P23458 3/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2A1 P68400 1/20 0.41
TYK2 P29597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22132768 0.88 EGFR (0.45) BTKEGFRFGFR4FGFR1JAK3
SCHEMBL30515900 0.82 FGFR1 (0.49) BTKFGFR4FGFR1
SCHEMBL22186345 0.81 RIPK1 (0.49) EGFRCSNK2A2CSNK2A1
SCHEMBL22132866 0.81 RIPK1 (0.49) EGFRCSNK2A2CSNK2A1
SCHEMBL23337029 0.80 FGFR4 (0.60) BTKFGFR4FGFR1
SCHEMBL23337047 0.80 FGFR4 (0.60) BTKFGFR4FGFR1
SCHEMBL23337058 0.80 FGFR4 (0.60) BTKFGFR4FGFR1
SCHEMBL29063774 0.80 FGFR4 (0.51) BTKFGFR4FGFR1
SCHEMBL22132909 0.78 FGFR1 (0.63) FGFR4FGFR1
SCHEMBL22132910 0.78 FGFR1 (0.63) FGFR4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3670513-B1 FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2023-09-20 EP disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 EP disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 WO disclosed